DiaGenic ASA Release: New Blood ''Signature'' Test Holds Key to Successful Early Alzheimer's Diagnosis and Treatment

WASHINGTON--(BUSINESS WIRE)--Leading experts agree that there is a clear need for a simple blood test for early Alzheimer’s disease. Early accurate diagnosis would enable the new generation of Alzheimer’s drugs to be successfully administered in the decisive first stages of the disease. Scientists working for Norwegian biotech company DiaGenic ASA are presenting the prototype of and results of initial trials of such a test at the Alzheimer’s Association International Conference on Prevention of Dementia in Washington June 9-12, 2007. Using peripheral blood as an easy-to-collect sample, the test detects a unique gene expression profile or “signature”. DiaGenic expects the test will be available to researchers in early 2008 paving the way for widespread use.